(1min)
A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed.
The Second U.S. Circuit Court of Appeals in Manhattan ruled that whistleblower Steven Camburn can
Gain access to the world’s leading investment community.
Already registered?
By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy
or
Top Stocks 2025
Virtual Investing Forum
Join us on January 8 as our VP of Quant Strategy, Steven Cress, discusses his 2025 Top 10 Stock Picks.
These picks are selected using the proven data-driven approach that led his 2024 picks to significantly outperform the S&P 500.*
*Performance as of December 6, 2024. Past performance is no guarantee of future results. Subject to Seeking Alpha’s Events Policy as available here: https://about.seekingalpha.com/events-policy.
| Symbol | Last Price | % Chg |
|---|---|---|
| NVS | 98.21 | -0.20% |
Market Cap
$195.00B
PE (TTM)
17.03
Yield
3.80%
Rev Growth (YoY)
8.92%
Short Interest
-
Prev. Close
$98.40
| Symbol | Last Price | % Chg |
|---|---|---|
| NVS | - | - |
| Novartis AG | ||
| AZN | - | - |
| AstraZeneca PLC | ||
| RHHBY | - | - |
| Roche Holding AG | ||
| PFE | - | - |
| Pfizer Inc. | ||
| MRK | - | - |
| Merck & Co., Inc. | ||
Jason Statham is a well-known English action movie actor. Recently, claims were spreading on social media platforms stating that he died in a flood in Texas, while some claimed he faced a tragic r...